mhurhangee/ep-ind-claims huggingface dataset:
Installation for casting under pressure with a permanent casting mould consisting of at least two casting mould parts, in particular of two casting mould halves, wherein at least one casting mould part can be pivoted, after opening the permanent casting mould, into a position in which the inner surface of this casting mould part can be handled, preferably by one person, in a work-facilitating and time-saving manner, characterized in that a rail system sunk in the floor or positioned on the floor is provided on which there is arranged at least one carriage for fully automatically receiving or removing and fully automatically delivering or transferring a furnace, wherein the carriage swings between a casting device of the counter-pressure or low-pressure die casting installation and a standby position situated remotely therefrom in such a way that the carriage receives a furnace at the standby position and transfers it into the casting device not yet provided with a furnace, or that the carriage removes a furnace from the casting device and delivers it to a free point of the standby position, in particular for reloading with melt, and the carriage is additionally provided for fully automatically receiving or removing and fully automatically delivering or transferring a casting mould or casting mould half, wherein the carriage swings between the casting device and a standby position situated remotely therefrom in such a way that the carriage receives a casting mould or casting mould half at the standby position and transfers it into the casting device not yet provided with a casting mould or casting mould half, or that the carriage receives a casting mould or casting mould half from the casting device and delivers it to a free point of the standby position for further use, in particular for intermediate storage or for exchange, wherein the carriage has at least two planes, wherein a lower plane is provided for fully automatically receiving or removing and fully automatically delivering or transferring the furnace, and an upper plane is provided for fully automatically receiving or removing and fully automatically delivering or transferring the casting mould or casting mould half.
A spinal facet joint prosthesis comprising: a crossbar, a first and a second cephalad arms (120,120') configured for implantation in conjunction with a first vertebral body, and a pair of caudal arms (150, 150') configured for implantation in conjunction with a second vertebral body; wherein the cooperative operation of the crossbar, the cephalad arms (120,120') and adaptable crossbar mounts (175,175') that join the cephalad arms (120,120') to the crossbar, interacting with the caudal arms (150,150') which form cups to receive the crossbar, is configurable to replace the facets of the spine, wherein the first cephalad arm comprises a spine reconstruction device for replacing bone, comprising an elongated tubular member with threads on a portion of an exterior of the elongated tubular member, and an aperture adapted to communicate with a bone surface. a crossbar, a first and a second cephalad arms (120,120') configured for implantation in conjunction with a first vertebral body, and a pair of caudal arms (150, 150') configured for implantation in conjunction with a second vertebral body; wherein the cooperative operation of the crossbar, the cephalad arms (120,120') and adaptable crossbar mounts (175,175') that join the cephalad arms (120,120') to the crossbar, interacting with the caudal arms (150,150') which form cups to receive the crossbar, is configurable to replace the facets of the spine, wherein the first cephalad arm comprises a spine reconstruction device for replacing bone, comprising an elongated tubular member with threads on a portion of an exterior of the elongated tubular member, and an aperture adapted to communicate with a bone surface.
An oligonucleotide which targets an Antiviral Gene natural antisense transcript for use as a therapeutic compound, wherein the oligonucleotide increases the expression of the Antiviral Gene, wherein the Antiviral Gene is IFNA1.
A method of reducing the amount of crystallized salt in an aqueous stream comprising: contacting the aqueous stream comprising one or more salts in solution with 0.1 to less than 1000 ppm of a salt inhibitor to reduce the amount of crystallized salt in the aqueous stream, and/or to reduce the amount of salt deposition from the aqueous stream that would otherwise occur in the absence of the salt inhibitor, wherein the salt inhibitor comprises an at least partially water soluble compound selected from: cadmium chloride, cadmium fluoride, cadmium bromide, cadmium iodide, and combinations thereof; or selected from: lead nitrate, lead nitrite, lead chloride, lead fluoride, lead bromide, lead iodide, and combinations thereof. contacting the aqueous stream comprising one or more salts in solution with 0.1 to less than 1000 ppm of a salt inhibitor to reduce the amount of crystallized salt in the aqueous stream, and/or to reduce the amount of salt deposition from the aqueous stream that would otherwise occur in the absence of the salt inhibitor, wherein the salt inhibitor comprises an at least partially water soluble compound selected from: cadmium chloride, cadmium fluoride, cadmium bromide, cadmium iodide, and combinations thereof; or selected from: lead nitrate, lead nitrite, lead chloride, lead fluoride, lead bromide, lead iodide, and combinations thereof.
A vehicle brake controller comprising: a master cylinder that generates a master cylinder pressure corresponding to a brake operation; a wheel cylinder (4FL, 4FR, 4RL and 4RR) arranged at a front or rear wheel to provide a hydraulic brake force corresponding to a wheel cylinder pressure to a corresponding one of the wheels; a brake hydraulic actuator installed between the master cylinder and the wheel cylinders (4FL, 4FR, 4RL and 4RR), the brake hydraulic actuator including a hydraulic pump driven by a pump motor, and a differential pressure valve that controls a differential pressure between the wheel cylinder pressure and the master cylinder pressure; a vehicle-stop-state motor-OFF controller (9 - step S9) configured to perform a vehicle-stop-state motor-OFF control that stops the pump motor upon the vehicle being stopped by the brake operation, and that maintains a stop state of the pump motor as is during stopping of the vehicle; and further characterized by a pressurization rate controller (9 - step S12 to step S16) configured to adjust a pressurization rate of the wheel cylinder pressure to a higher value as a road surface gradient becomes larger, upon resuming operation of the pump motor after the vehicle-stop-state motor-OFF control ends due to acceleration from the vehicle stop state. a master cylinder that generates a master cylinder pressure corresponding to a brake operation; a wheel cylinder (4FL, 4FR, 4RL and 4RR) arranged at a front or rear wheel to provide a hydraulic brake force corresponding to a wheel cylinder pressure to a corresponding one of the wheels; a brake hydraulic actuator installed between the master cylinder and the wheel cylinders (4FL, 4FR, 4RL and 4RR), the brake hydraulic actuator including a hydraulic pump driven by a pump motor, and a differential pressure valve that controls a differential pressure between the wheel cylinder pressure and the master cylinder pressure; a vehicle-stop-state motor-OFF controller (9 - step S9) configured to perform a vehicle-stop-state motor-OFF control that stops the pump motor upon the vehicle being stopped by the brake operation, and that maintains a stop state of the pump motor as is during stopping of the vehicle; and further characterized by a pressurization rate controller (9 - step S12 to step S16) configured to adjust a pressurization rate of the wheel cylinder pressure to a higher value as a road surface gradient becomes larger, upon resuming operation of the pump motor after the vehicle-stop-state motor-OFF control ends due to acceleration from the vehicle stop state.
A method of making an allogenic lymphocyte composition comprising: providing a peripheral blood cell composition from a human donor allogenic to the recipient, the peripheral blood cell composition comprising CD4+ T-cells, CD8+ T-cells, and natural killer cells, wherein (i) the donor comprises at least one human leukocyte antigen Class II allele mismatch relative to the recipient in the donor versus the recipient direction and the HLA Class II allele mismatch is at a gene selected from the group consisting of HLA-DRB1, HLA-DQB1, and HLA-DPB1, and (ii) the recipient does not have detectable antibodies reactive against human leukocyte antigens of the donor; and making the allogenic lymphocyte composition from the peripheral blood cell composition by reducing the number of CD8+ T-cells in the peripheral blood cell composition by at least one order of magnitude, wherein (a) the number of CD4+ T-cells in the allogenic lymphocyte composition differs from the number of CD4+ T-cells in the peripheral blood cell composition by less than about 50%, and (b) the number of natural killer cells in the allogenic lymphocyte composition is less than or equal to the number of natural killer cells in the peripheral blood cell composition, with the proviso that the CD4+ T-cells of the allogenic lymphocyte composition are not activated ex vivo. providing a peripheral blood cell composition from a human donor allogenic to the recipient, the peripheral blood cell composition comprising CD4+ T-cells, CD8+ T-cells, and natural killer cells, wherein (i) the donor comprises at least one human leukocyte antigen Class II allele mismatch relative to the recipient in the donor versus the recipient direction and the HLA Class II allele mismatch is at a gene selected from the group consisting of HLA-DRB1, HLA-DQB1, and HLA-DPB1, and (ii) the recipient does not have detectable antibodies reactive against human leukocyte antigens of the donor; and making the allogenic lymphocyte composition from the peripheral blood cell composition by reducing the number of CD8+ T-cells in the peripheral blood cell composition by at least one order of magnitude, wherein (a) the number of CD4+ T-cells in the allogenic lymphocyte composition differs from the number of CD4+ T-cells in the peripheral blood cell composition by less than about 50%, and (b) the number of natural killer cells in the allogenic lymphocyte composition is less than or equal to the number of natural killer cells in the peripheral blood cell composition, with the proviso that the CD4+ T-cells of the allogenic lymphocyte composition are not activated ex vivo.
Optical device comprising: - a source electrode; - a drain electrode; - a gap area between the source electrode and the drain electrode; - a cluster being positioned in the gap area for connecting and disconnecting the source electrode and the drain electrode and for changing optical and/or plasmonic properties of the gap area, the cluster being configured to adopt at least two different states, wherein in one state one or more atoms and/or one or more molecules of the cluster is/are arranged such that the source electrode and the drain electrode are electrically connected, and wherein in another state the one or more atoms and/or the one or more molecules of the cluster is/are arranged such that the source electrode and the drain electrode are electrically disconnected; and - an optical coupling element for bringing light into and/or out of the gap area. - a source electrode; - a drain electrode; - a gap area between the source electrode and the drain electrode; - a cluster being positioned in the gap area for connecting and disconnecting the source electrode and the drain electrode and for changing optical and/or plasmonic properties of the gap area, the cluster being configured to adopt at least two different states, wherein in one state one or more atoms and/or one or more molecules of the cluster is/are arranged such that the source electrode and the drain electrode are electrically connected, and wherein in another state the one or more atoms and/or the one or more molecules of the cluster is/are arranged such that the source electrode and the drain electrode are electrically disconnected; and - an optical coupling element for bringing light into and/or out of the gap area.
A system for controlling a vehicle drivetrain comprising an engine, a motor/generator and a clutch disposed between the engine and the motor/generator and having a controllable torque transfer capacity, the system comprising: control means for selectively operating the vehicle in a hybrid operating mode in which the clutch is engaged and in an electric operating mode in which the clutch is disengaged; characterized in that the control means is arranged to select a mode transition pattern from a plurality of predetermined mode transition patterns for disengaging the clutch and stopping the engine when an operating mode is changed from the hybrid operating mode to the electric operating mode in dependence on a required driving force of the vehicle. control means for selectively operating the vehicle in a hybrid operating mode in which the clutch is engaged and in an electric operating mode in which the clutch is disengaged;
Composition (C 1) presented in the form of an oil-in-water type emulsion, characterised in that it comprises for 100% of its weight: - 5% to 55% by weight, more particularly 7% to 30% by weight and even more particularly 10% to 20% by weight, of a fatty phase (P 1) consisting of at least one oil and optionally at least one wax, - 0.06% to 4.5% by weight of at least one cross-linked anionic polyelectrolyte resulting from the polymerisation of partially or completely salified 2-methyl 2-[(1-oxy 2-propenyl)amino] 1-propane sulfonic acid, with at least one neutral monomer selected from N,N-dialkyl acrylamides, wherein each of the alkyl groups comprises between one and four carbon atoms, and at least one monomer of formula: wherein R represents a linear or branched alkyl radical comprising eight to twenty carbon atoms and n represents a number greater than or equal to one and less than or equal to twenty, in the presence of at least one cross-linking agent; - 0.0025% to 1% by weight xanthan gum, - 0.0025% to 1% by weight acacia gum, - 38.5% to 94.935% by weight of a cosmetically acceptable aqueous phase (P 2), said aqueous phase (P 2) comprising for 100% of its weight 1% to 10% by weight of at least one salt in a dissolved form, said composition (C 1) also being characterised in that the weight ratio between the xanthan gum and the acacia gum is greater than or equal to 1/3 and less than or equal to 3/1. - 5% to 55% by weight, more particularly 7% to 30% by weight and even more particularly 10% to 20% by weight, of a fatty phase (P 1) consisting of at least one oil and optionally at least one wax, - 0.06% to 4.5% by weight of at least one cross-linked anionic polyelectrolyte resulting from the polymerisation of partially or completely salified 2-methyl 2-[(1-oxy 2-propenyl)amino] 1-propane sulfonic acid, with at least one neutral monomer selected from N,N-dialkyl acrylamides, wherein each of the alkyl groups comprises between one and four carbon atoms, and at least one monomer of formula: wherein R represents a linear or branched alkyl radical comprising eight to twenty carbon atoms and n represents a number greater than or equal to one and less than or equal to twenty, in the presence of at least one cross-linking agent; - 0.0025% to 1% by weight xanthan gum, - 0.0025% to 1% by weight acacia gum, - 38.5% to 94.935% by weight of a cosmetically acceptable aqueous phase (P 2), said aqueous phase (P 2) comprising for 100% of its weight 1% to 10% by weight of at least one salt in a dissolved form,
A compound of general formula for use in analgesia wherein R 1 is -OH, -OR 4, -O-2,4-dinitrophenyl, -OC(=O)C 1-6 alkyl, -OC(=O)phenyl, -OC(=O)pyridyl; R 2 is hydrogen, -OH, -OR 4, -Cl, -N 3, bis(2-chloroethyl)amino-, -OC(=O)-C 1-16 alkyl, -OC(=O)phenyl, -OC(=O)pyridyl, -(N-methyl-N-C(=O)-CH=CH-fur-3-yl), and the dot-ted line is absent or R 2 is -O, -CH 2, -N-NH 2, -NOH, -N-O-C 1-6 alkyl wherein the alkyl is optionally substituted with a caboxyl group, and the dotted line represents a chemical bond, R 3 is hydrogen, -O, -C 1-6 alkyl optionally substituted by phenyl, (C 3-7 cycloalkyl)-(C 1-6 al-kyl)-, -(C 1-6 alkyl)-O-(C 1-6 alkyl), -C 2-7 alkenyl; R 4 is -C 1-6 alkyl optionally substituted by a phenyl or by a 6 membered saturated heterocycle attached by a nitrogen and containing at least one more heteroatom selected from O, S and N; R 5 is absent or is -C 1-6 alkyl and the ring nitrogen bears a positive charge; R 6 is hydrogen, -C 1-6 alkyl; X is hydrogen, -OH, -OR 4, -O-cinnamoyl, -NH(C 1-6 alkyl); D is deuterium and stereoisomers including enantiomers, diastereomers, racemic mixtures, mixtures of enantiomers or combinations thereof, as well as polymorphs, tautomers, solvates, salts, esters thereof. R 1 is -OH, -OR 4, -O-2,4-dinitrophenyl, -OC(=O)C 1-6 alkyl, -OC(=O)phenyl, -OC(=O)pyridyl; R 2 is hydrogen, -OH, -OR 4, -Cl, -N 3, bis(2-chloroethyl)amino-, -OC(=O)-C 1-16 alkyl, -OC(=O)phenyl, -OC(=O)pyridyl, -(N-methyl-N-C(=O)-CH=CH-fur-3-yl), and the dot-ted line is absent or R 2 is -O, -CH 2, -N-NH 2, -NOH, -N-O-C 1-6 alkyl wherein the alkyl is optionally substituted with a caboxyl group, and the dotted line represents a chemical bond, R 3 is hydrogen, -O, -C 1-6 alkyl optionally substituted by phenyl, (C 3-7 cycloalkyl)-(C 1-6 al-kyl)-, -(C 1-6 alkyl)-O-(C 1-6 alkyl), -C 2-7 alkenyl; R 4 is -C 1-6 alkyl optionally substituted by a phenyl or by a 6 membered saturated heterocycle attached by a nitrogen and containing at least one more heteroatom selected from O, S and N; R 5 is absent or is -C 1-6 alkyl and the ring nitrogen bears a positive charge; R 6 is hydrogen, -C 1-6 alkyl; X is hydrogen, -OH, -OR 4, -O-cinnamoyl, -NH(C 1-6 alkyl); D is deuterium
Method for a train control system, - wherein a modulated activation signal (36; 56) is formed by means of a vehicle-side transmission facility (12; 17) by modulation from an activation signal (34; 54) and an information signal (35; 55) and is transmitted via a transmission channel (38; 58) to a wayside transmission facility (16; 19), - wherein the wayside transmission facility (16; 19) determines the information signal (35; 55) by demodulation of the modulated activation signal (36; 56), - wherein by means of the information signal (35; 55) at least one specific item of information, which is contained in the information signal (35; 55) and which specifies a track-bound vehicle provided with the vehicle-side transmission device (12; 17) is transmitted, - wherein the wayside transmission facility (16; 19) outputs the information signal (35; 55) for further processing on an interface and - wherein in addition to the information signal (35; 55) the wayside transmission facility (16; 19) outputs an additional information signal (43; 63), which contains at least one additional item of information (44; 64) which specifies the wayside transmission facility (16; 19) and/or its location, for further processing on the one interface (41; 61) or on an additional interface, characterised in that a central control facility, in particular in the form of a signal box, receives the information signal (35; 55) and the additional information signal (43; 63) by way of a wayside electronic unit (14; 18) and further processes both information signals (35, 43; 55, 63) for determining the position of the vehicle. - wherein a modulated activation signal (36; 56) is formed by means of a vehicle-side transmission facility (12; 17) by modulation from an activation signal (34; 54) and an information signal (35; 55) and is transmitted via a transmission channel (38; 58) to a wayside transmission facility (16; 19), - wherein the wayside transmission facility (16; 19) determines the information signal (35; 55) by demodulation of the modulated activation signal (36; 56), - wherein by means of the information signal (35; 55) at least one specific item of information, which is contained in the information signal (35; 55) and which specifies a track-bound vehicle provided with the vehicle-side transmission device (12; 17) is transmitted, - wherein the wayside transmission facility (16; 19) outputs the information signal (35; 55) for further processing on an interface and - wherein in addition to the information signal (35; 55) the wayside transmission facility (16; 19) outputs an additional information signal (43; 63), which contains at least one additional item of information (44; 64) which specifies the wayside transmission facility (16; 19) and/or its location, for further processing on the one interface (41; 61) or on an additional interface,
A package for sale to a consumer containing tobacco material for combustible smoking articles, the package comprising: outer packaging including branding or product information; a sealed inner pouch within the outer packaging; and pasteurised tobacco material within the sealed inner pouch, the pasteurised tobacco material comprising tobacco material for combustible smoking articles, the tobacco material having a cut width of between 0.3 mm and 0.9 mm. outer packaging including branding or product information; a sealed inner pouch within the outer packaging; and pasteurised tobacco material within the sealed inner pouch, the pasteurised tobacco material comprising tobacco material for combustible smoking articles, the tobacco material having a cut width of between 0.3 mm and 0.9 mm.